About: Outcome of COVID‐19 in multiple myeloma patients in relation to treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcome of COVID‐19 in multiple myeloma patients in relation to treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
Creator	Ljunggren, Hans-Gustaf Gran, Charlotte Nahi, Hareth Susek, Katharina Alici, \| Gran, \|
Source	Medline; PMC
abstract	COVID‐19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID‐19. Studies are ongoing to decipher the risk factors and risk groups among cancer patients as well as strategies to refine treatment approaches. Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide‐based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID‐19. We report that patients that succumbed to COVID‐19 presented with either progressive tumor disease under daratumumab treatment or were in remission under lenalidomide‐dexamethasone treatment.
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1111/ejh.13502
bibo:pmid	32745304
has license	cc-by-nc
sha1sum (hex)	41d2dc0f772c15aa23be5310d5683ab167fd39b2
schema:url	https://doi.org/10.1111/ejh.13502
resource representing a document's title	Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
has PubMed Central identifier	PMC7436812
has PubMed identifier	32745304
schema:publication	Eur J Haematol
resource representing a document's body	covid:41d2dc0f772c15aa23be5310d5683ab167fd39b2#body_text
is schema:about of	named entity 'patients' named entity 'TREATMENT' named entity 'COMBINATION' named entity 'TUMOR DISEASE' named entity 'TREATMENTS' named entity 'PROGRESSIVE' named entity 'REPORTED' named entity 'GLOBAL' named entity 'STUDIES' named entity 'EITHER' named entity 'DEXAMETHASONE' named entity 'MULTIPLE MYELOMA' named entity 'adverse outcome' named entity 'smoldering multiple myeloma' named entity 'disease' named entity 'risk factors' named entity 'COVID-19' named entity 'dexamethasone' named entity 'immunoglobulin' named entity 'dry cough' named entity 'dexamethasone' named entity 'clinical presentation' named entity 'loss of taste' named entity 'symptom' named entity 'daratumumab' named entity 'obesity' named entity 'global pandemic' named entity 'bortezomib' named entity 'PCR' named entity 'PFS' named entity 'pomalidomide' named entity 'symptom' named entity 'International Myeloma Working Group' named entity 'dexamethasone' named entity 'cyclophosphamide' named entity 'bortezomib' named entity 'COVID' named entity 'monoclonal antibodies' named entity 'ageusia' named entity 'lenalidomide' named entity 'proteasome inhibitors' named entity 'bortezomib' named entity 'lenalidomide' named entity 'multiple myeloma' named entity 'lenalidomide' named entity 'dexamethasone' named entity 'immunoglobulin' named entity 'dyspnea' named entity 'daratumumab' named entity 'nasopharyngeal swabs' named entity 'dexamethasone' named entity 'COVID-19' named entity 'dexamethasone' named entity 'dexamethasone' named entity 'dexamethasone' named entity 'hypogammaglobulinemia' named entity 'Risk factors' named entity 'coronavirus disease 2019' named entity 'multiple myeloma' named entity 'thalidomide' named entity 'Pathogenesis' named entity 'daratumumab' named entity 'COVID' named entity 'dexamethasone' named entity 'lenalidomide' named entity 'immunomodulatory drugs' named entity 'COVID-19' named entity 'COVID-19' named entity 'remission' named entity 'adverse outcome' named entity 'malignancy' named entity 'adverse outcome' named entity 'complete response' named entity 'dexamethasone' named entity 'iatrogenic' named entity 'progression-free survival'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software